Drugs / mRNA-1215
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05398796 | Jul 2022 → Sep 2024 | Nipah virus disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-07-12 | ModernaTX, Inc. | Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215 q4web.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA -1215 | “The investigational mRNA-1215 vaccine is a lipid nanoparticle dispersion containing mRNA that encodes for a secreted prefusion stabilized F component covalently linked to a G...” NCT05398796 ↗1“Biological: mRNA -1215” NCT05398796 ↗ |
| Modality | Messenger RNA (mRNA) | “a Nipah virus (NiV) mRNA vaccine” NCT05398796 ↗ |
| Route | Intramuscular | “received mRNA-1215 via intramuscular (IM) injection” NCT05398796 ↗ |